AF RISK

Identification of a risk profile to guide atrial fibrillation therapy

3 Current vacancy for AF RISK

Arts-onderzoeker (ritmestoornissen)

Project: AF RISK, RACE 9, RACE‐8‐HF, RASTA AF Research line: Atrial Fibrillation

More about this vacancy

MD/PhD students

Project: BIOSTAT-CHF, Early Synergy, GIPS-IV trial, iPHORECAST, KETONE-HF, PLN cardiomyopathy, RACE‐8‐HF, RED-CVD, SECRETE-HF, STOP-HF, APAF-CRT, AF RISK, Adiposity in Heart Failure with Preserved Ejection Fraction, RASTA AF, RACE 9, Selenium and Heart Failure Research line: Heart Failure, Ischemic Heart Diseases, Experimental Cardiology, Atrial Fibrillation

More about this vacancy

Bachelor and Master students

Project: BIOSTAT-CHF, Early Synergy, GIPS-IV trial, Adiposity in Heart Failure with Preserved Ejection Fraction, iPHORECAST, KETONE-HF, RACE‐8‐HF, RED-CVD, SECRETE-HF, Selenium and Heart Failure, STOP-HF, PLN cardiomyopathy, AF RISK, APAF-CRT, RACE 9, RASTA AF Research line: Heart Failure, Ischemic Heart Diseases, Experimental Cardiology, Atrial Fibrillation

More about this vacancy

Rationale: AF is a progressive disease, but identifying patients at risk for AF progression is challenging.

Objective: The aim of this study is to identify factors such as clinical information, echocardiographic parameters and circulating biomarkers, that can be used in a risk profile to predict success of rhythm control and to optimize therapy in patients with short-lasting paroxysmal or persistent AF.

Study design: multi-center, prospective, observational study.

Objective: To identify factors such as clinical information, echocardiographic parameters and circulating biomarkers, that can be used in a risk profile to predict success of rhythm control and to optimize therapy in patients with short-lasting paroxysmal or persistent AF.

Study design and outcomes: 499 consecutive patients were included presenting with short-lasting symptomatic paroxysmal or persistent AF in whom a rhythm control strategy was preferred. Clinical factors, echocardiographic parameters, endothelial function measurements and blood samples for analysis of circulating biomarkers were collected. Patients were regularly seen during a 1-year-follow up and rhythm monitoring was performed by Holter and 2-week event recording.

We have found in patients in AFRISK that left atrial volume, NT-proBNP, and PAI-1 were associated with AF progression. Patients with AF progression had a higher event rate.

People involved

Principal investigators

Isabelle van Gelder

Cardiologist

Michiel Rienstra

Cardiologist
Team

Isabelle van Gelder

Cardiologist

Michiel Rienstra

Cardiologist

Vicente Artola Arita

PhD Student

Press & publications

Atrial fibrillation progression risk factors and associated cardiovascular outcome in well-phenotyped patients: data from the AF-RISK study

Ruben R De With, Ernaldo G Marcos, Elton A M P Dudink, Henri M Spronk, Harry J G M Crijns, Michiel Rienstra, Isabelle C Van Gelder. Europace. 2019

view on publisher site

External links